Jennison Associates LLC Sells 3,247 Shares of Integra Lifesciences Holdings Corp (IART)
Jennison Associates LLC lessened its holdings in Integra Lifesciences Holdings Corp (NASDAQ:IART) by 0.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,011,455 shares of the life sciences company’s stock after selling 3,247 shares during the quarter. Jennison Associates LLC owned 1.19% of Integra Lifesciences worth $66,625,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. GSA Capital Partners LLP acquired a new stake in Integra Lifesciences in the second quarter worth about $538,000. Paloma Partners Management Co purchased a new position in shares of Integra Lifesciences in the second quarter worth about $12,012,000. Bank of Montreal Can raised its stake in shares of Integra Lifesciences by 55.8% in the second quarter. Bank of Montreal Can now owns 16,018 shares of the life sciences company’s stock worth $1,031,000 after purchasing an additional 5,739 shares during the last quarter. MetLife Investment Advisors LLC raised its stake in shares of Integra Lifesciences by 52.6% in the second quarter. MetLife Investment Advisors LLC now owns 44,336 shares of the life sciences company’s stock worth $2,856,000 after purchasing an additional 15,286 shares during the last quarter. Finally, Sei Investments Co. raised its stake in shares of Integra Lifesciences by 12.1% in the second quarter. Sei Investments Co. now owns 179,756 shares of the life sciences company’s stock worth $11,578,000 after purchasing an additional 19,377 shares during the last quarter. 85.55% of the stock is owned by institutional investors and hedge funds.
Shares of IART stock opened at $52.37 on Tuesday. The company has a debt-to-equity ratio of 1.04, a current ratio of 3.20 and a quick ratio of 2.08. The company has a market cap of $4.62 billion, a P/E ratio of 22.52, a P/E/G ratio of 1.69 and a beta of 0.76. Integra Lifesciences Holdings Corp has a twelve month low of $45.96 and a twelve month high of $67.50.
Several research analysts have recently issued reports on the company. Zacks Investment Research upgraded Integra Lifesciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 9th. BidaskClub cut Integra Lifesciences from a “buy” rating to a “hold” rating in a research note on Friday, July 27th. Cantor Fitzgerald restated a “hold” rating and issued a $59.00 price objective on shares of Integra Lifesciences in a research note on Wednesday, July 25th. Oppenheimer restated a “buy” rating and issued a $74.00 price objective on shares of Integra Lifesciences in a research note on Wednesday, July 25th. Finally, Morgan Stanley set a $68.00 price objective on Integra Lifesciences and gave the stock a “hold” rating in a research note on Thursday, October 11th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $61.92.
In related news, Director Barbara B. Hill purchased 3,705 shares of Integra Lifesciences stock in a transaction that occurred on Monday, November 5th. The stock was bought at an average cost of $53.90 per share, for a total transaction of $199,699.50. Following the completion of the transaction, the director now owns 63,381 shares in the company, valued at $3,416,235.90. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Richard E. Caruso sold 46,676 shares of Integra Lifesciences stock in a transaction that occurred on Wednesday, October 17th. The shares were sold at an average price of $63.19, for a total value of $2,949,456.44. Following the transaction, the insider now owns 134,134 shares of the company’s stock, valued at $8,475,927.46. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by company insiders.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Recommended Story: Cash Flow Analysis in Stock Selection
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.